Newsroom

Press Releases and Media Coverage

Press Release
April 15 2026
Verismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development
MORE >
Press Release
March 18 2026
Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data – Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynKIR™-310 – at AACR Annual Meeting 2026
MORE >
Press Release
December 9 2025
Verismo Therapeutics Shares Positive Preclinical Data at ASH 2025 Comparing SynKIR™-310 With Conventional CAR-T
MORE >
Press Release
November 10 2025
Verismo Therapeutics Presents Promising Preclinical Data at SITC 2025 for SynKIR™-110 in Solid Tumors
MORE >
Press Release
November 5 2025
Verismo Therapeutics to Announce Upcoming Presentations at SITC and ASH Annual Meetings
MORE >
Press Release
October 23 2025
Verismo Therapeutics to Present at iMig 2025
MORE >
Press Release
October 2 2025
Verismo Therapeutics Treats First Follicular Lymphoma Patient in CELESTIAL-301 Trial, Strengthening Collaboration with IFLI
MORE >
Press Release
September 25 2025
Verismo Therapeutics Announces Partnership with Miltenyi Biotec to Support Advancing Clinical Programs
MORE >
Press Release
July 29 2025
Verismo Therapeutics Named One of Philadelphia Business Journal’s 2025 Best Places to Work for Third Consecutive Year
MORE >
Press Release
May 23 2025
Verismo Therapeutics Provides Updates on Upcoming Poster Presentation at ASCO 2025
MORE >